The “Terbinafine Treatment of Axial Spondyloarthropathy” study, financed by the Malassezia Foundation, has entered the enrollment phase.
Montreal, 2021/11/22 - The Malassezia Foundation is pleased to report that a study evaluating the effects of the widely-used antifungal drug terbinafine in axial spondyloarthritis has begun recruiting. More information about study design can be found at clinicaltrials.gov.
Martin Laurence, the Foundation’s president, said:
“We’re really glad this important study has moved into the enrollment phase. We're proud of collaborating with a prestigious research institution such as OHSU, and we'd like to thank the Spondylitis Association of America for featuring this study on their "Participate in Research" webpage. We hope this collective effort will help advance science and benefit patients.”
If you wish to know more about this development or about the Foundation’s activities, please get in touch with us through our Contact page.